Alpha Power and Functional Connectivity in Cognitive Decline:A Systematic Review and Meta-Analysis by Lejko, Nena et al.
 
 
 University of Groningen
Alpha Power and Functional Connectivity in Cognitive Decline
Lejko, Nena; Larabi, Daouia I; Herrmann, Christoph S; Aleman, André; Ćurčić-Blake,
Branislava
Published in:
Journal of Alzheimer’s Disease
DOI:
10.3233/JAD-200962
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2020
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Lejko, N., Larabi, D. I., Herrmann, C. S., Aleman, A., & Ćurčić-Blake, B. (2020). Alpha Power and
Functional Connectivity in Cognitive Decline: A Systematic Review and Meta-Analysis. Journal of
Alzheimer’s Disease, 78(3), 1047-1088. https://doi.org/10.3233/JAD-200962
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 26-12-2020
1461
Hepatology, Vol. 72, No. 4, 2020  
Unequal Effects of Myosin 5B Mutations 
in Liver and Intestine Determine the 
Clinical Presentation of Low-Gamma-
Glutamyltransferase Cholestasis
Sven C.D. van IJzendoorn ,1 Qinghong Li ,1 Yi-ling Qiu ,2,3 Jian-She Wang ,2,3 and Arend W. Overeem 1
Myosin 5B–Associated 
Cholestatic Liver Disease
Cholestatic liver disease (CLD) is characterized by 
an increase in the serum concentrations of compounds 
that are normally excreted with bile, such as bile 
acids and bilirubin.(1) CLD clinically manifest with 
cholestasis, jaundice, and pruritis. Diagnosis involves 
evaluation of the patient’s clinical manifestations, 
exclusion of common causes of childhood cholestasis, 
and analyses of blood biochemistry and liver histol-
ogy.(1) One blood marker that aids in the differential 
diagnosis of liver diseases is gamma-glutamyltransfer-
ase (GGT), a liver enzyme which is typically elevated 
in serum upon liver damage. The best known CLDs 
characterized by low/normal GGT are the benign 
recurrent and progressive forms of familial intrahe-
patic cholestasis (BRIC/PFIC), which are caused by 
mutations in the adenosine triphosphatase phospho-
lipid transporting 8B1 (ATP8B1) gene encoding the 
ATP8B1 protein (BRIC/PFIC1) or in the adenos-
ine triphosphate–binding cassette family B member 
11 (ABCB11) gene encoding the canalicular bile salt 
export pump (BSEP) (BRIC/PFIC2).(2,3) In hepato-
cytes, ATP8B1 and BSEP are localized to the apical 
bile canalicular domain, where they contribute to bili-
ary secretion. When mutated as in PFIC1/2 patients, 
the respective proteins are less expressed or mislocal-
ized and/or display impaired activity, leading to defec-
tive biliary secretion and, consequently, cholestasis.(2,3)
Since 2017 four independent reports have identi-
fied in total 30 different myosin 5B (MYO5B) muta-
tions in 22 patients with non–microvillus inclusion 
disease (MVID) who were diagnosed with intermit-
tent, recurrent, or progressive cholestasis presenting 
with jaundice, pruritus, hepatomegaly, and low/normal 
serum levels of GGT (Fig.  1; Supporting Table S1). 
These patients tested negative for mutations in other 
PFIC-associated genes.(4-7) MYO5B mutations may 
account for approximately 20% of pediatric patients 
with idiopathic low-GGT intrahepatic cholestasis.(8) 
Abbreviations: ABCB11, adenosine triphosphate–binding cassette family B member 11; ATP8B1, adenosine triphosphatase phospholipid 
transporting 8B1; BRIC/PFIC, benign recurrent and progressive forms of familial intrahepatic cholestasis; BSEP, bile salt export pump; CLD, 
cholestatic liver disease; GGT, gamma-glutamyltransferase; MRP2, multidrug resistance–associated protein 2; MVID, microvillus inclusion disease; 
MYO5B, myosin 5B; PTC, premature termination codon; TPN, total parenteral nutrition.
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Based on microscopic analyses of liver biopsies, a 
reduced expression or mislocalization of BSEP was 
reported(4,5) but not in all patients.(7)
MYO5B mutations were earlier reported to cause 
MVID.(9) MVID is a severe congenital enteropathy, 
characterized by severe intractable secretory diarrhea 
from the moment of birth and the inability to absorb 
any nutrients.(10) Diagnosis involves evaluation of the 
patient’s clinical manifestations, exclusion of common 
causes of diarrhea, and inspection of small intestinal 
biopsies. MVID small intestinal tissue reveals (near-) 
total villus atrophy and, at the cellular level, microvil-
lus atrophy and mislocalization of many apical brush 
border proteins including the diagnostic brush border 
protein cluster of differentiation 10.(10,11) The pres-
ence of microvillus inclusion bodies in the enterocytes 
by electron microscopy confirms the diagnosis. Tissue 
and cellular defects are seen throughout the intes-
tine(12) and have been causally related to the loss of 
function of the encoded myosin Vb protein. For their 
survival, patients with MVID require lifelong total 
parenteral nutrition (TPN) and, in some cases, intes-
tinal transplantation.(13,14)
A significant number of patients with MVID pres-
ent CLD with low/normal serum GGT levels, man-
ifesting as jaundice (associated with elevated levels 
of conjugated serum bilirubin), pruritus, and hepato-
megaly.(13,15) The prevalence of CLD in patients with 
MVID has been estimated at ~30% in a local cohort of 
28 patients.(15) We have extracted data from all pub-
lished MVID case reports until 2020 (reporting on 
133 patients with MVID) (Supporting Table S1) and 
calculated the prevalence of MVID-associated CLD 
to be 37%. When we restricted the analyses to only 
patients with MVID and reported MYO5B mutations, 
the prevalence was 54%. It is possible that this is an 
underestimation as patients with MVID who were 
still alive at the moment of publication of their case 
report could have developed CLD later on.
Microscopic analyses of liver biopsies of patients 
with MVID and MYO5B mutations showed a reduced 
expression and/or mislocalization of BSEP, which is 
considered a major factor in the severity of cholesta-
sis.(16) Further, a reduced expression and/or mislo-
calization of the bilirubin and bile acid transporter 
multidrug resistance–associated protein 2 (MRP2) 
was shown in some,(17) but not all,(14) patients with 
MVID. Mutations in the MRP2-coding adenosine 
triphosphate–binding cassette family C member 2 
gene cause Dubin-Johnson syndrome associated with 
elevated conjugated bilirubin levels in serum.(18,19) 
The expression or canalicular localization of ATP8B1 
in liver biopsies of patients with MVID has not been 
studied. The mislocalization of MRP2, which is not 
typically observed in patients with ABCB11 muta-
tions, indicates that MYO5B mutations can affect 
multiple canalicular transporters in parallel.
Because MYO5B mutations disrupt the intra-
cellular trafficking of brush border proteins in the 
intestine,(20,21) it has been assumed that the same 
MYO5B mutations similarly disrupt the trafficking of 
the canalicular bile acid–transporting and bilirubin- 
transporting proteins in the liver.(9) While this seems 
plausible and is supported by cell culture studies,(22) 
not all data are in support of this. For example, in 
other patients with MVID and MYO5B mutations 
and presenting with CLD no mislocalization of these 
canalicular transporters was reported, and CLD later 
resolved.(23) In another patient without MVID diag-
nosed with CLD and MYO5B mutations no mislo-
calization of BSEP was observed.(7) Furthermore, 
5 patients with MVID showed reduction of cholesta-
sis and pruritus when soybean oil–based lipids in the 
TPN were replaced by fish oil–based lipids, indicating 
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TPN as a contributing factor in cholestasis and pru-
ritus in at least these patients with MVID.(8,24,25) 
The prevalence of TPN-associated CLD in pediatric 
cohorts was estimated to be between 20% (< 1 month 
of TPN) and 70% (> 2 months of TPN).(26,27) Given 
their lifelong TPN dependency,(6) a prevalence of 
CLD of 37%-54% in patients with MVID seems 
rather low. Clearly, with these prevalence numbers 
at hand, it is difficult to conclude whether CLD in 
TPN-dependent patients with MVID is caused by the 
TPN or the patient’s MYO5B mutations. Nonetheless, 
it appears that pathogenic MYO5B mutations may 
not always affect bile canalicular protein localization 
and/or cause CLD.
CoRRelatIoNS BetWeeN MYO5B 
geNotype aND ClD
Similar to the 37%-54% of patients diagnosed 
with MVID presenting symptoms of CLD, 21% of 
patients diagnosed with low/normal-GGT CLD 
were reported to present loose stools or diarrheal 
episodes.(4,5,7) Overlap of symptoms thus occurs, but 
there are more MVID patients who present cholestasis 
than there are patients with CLD who present diar-
rhea. An outstanding question is why MYO5B muta-
tions cause either CLD or MVID with or without 
symptoms of MVID or CLD, respectively. Possibly, 
the type of MYO5B mutation may play a role. While 
the many private MYO5B mutations running in the 
affected families complicate a detailed explanation, 
some generalizations can be made. For example, it was 
suggested that in patients with isolated CLD MYO5B 
mutations may not result in sufficient loss of myosin 
Vb protein function to cause intestinal failure. This 
was supported by in silico analyses based on the myo-
sin Vb homology protein structure. These revealed 
that the compound heterozygous patients with iso-
lated CLD often carried in one allele a mutation 
that corresponded to more peripheral residues of the 
motor domain that were predicted to be less damag-
ing for the protein’s motor function.(28) Further, sev-
eral MYO5B mutations associated with isolated CLD 
give rise to amino acid substitutions that normally 
occur in other species, suggesting that these do not 
significantly affect the protein function. Thus, CLD 
in patients without MVID appears to be a manifes-
tation of relatively mild MYO5B mutations.(4,28) Why 
relatively mild MYO5B mutations that cause a liver 
defect would not cause intestinal defects is not known. 
Possibly, the higher expression level of MYO5B in the 
intestine (https://www.gtexp ortal.org/home/gene/
MYO5B) may compensate for a lower per-protein 
activity.
An additional correlation between MYO5B geno-
type and isolated CLD has been observed. That is, 
isolated CLD did not involve any patient with bial-
lelic nonsense or frameshift mutations in MYO5B that 
induce a premature termination codon (PTC) and 
affect the C-terminal rab11a-binding domain.(4,28) 
A molecular mechanism to explain this genotype– 
phenotype correlation in CLD was recently pro-
posed.(29) Thus, the expression of an MVID-associated 
and CLD-associated MYO5B missense mutation 
(c.1979C  >  T), but not nonsense mutations, in a 
MYO5B-depleted human hepatoma cell line caused 
the mislocalization of MRP2 and other bile canalicu-
lar transporter proteins. Depletion of MYO5B in these 
cells or in the mouse liver as such did not result in the 
mislocalization of these canalicular transporters. The 
discordant effect of missense versus PTC-inducing 
MYO5B mutations suggested that the mutant myo-
sin Vb protein exerted a gain-of-toxic function. It was 
shown that this gain-of-toxic function required the 
carboxyl terminus of the mutant myosin Vb protein. 
Protein-truncating mutations cause loss of the myosin 
Vb protein or synthesis of a protein that lacks this 
carboxyl terminus, which explains, at least from the 
perspective of the studied canalicular transporters, 
why isolated CLD does not appear to correlate well 
with PTC-inducing MYO5B mutations.(29)
The relationship between PTC-inducing MYO5B 
mutations and the occurrence of CLD in patients with 
MVID has not been studied. Therefore, we exam-
ined the published MVID case reports (Supporting 
Table S1) and the international MVID registry (www.
mvid-centr al.org) and extracted information about 
the mutation and presence of CLD. Details regard-
ing the mutations and the presence or absence of 
CLD were reported for 22 patients with MVID and 
biallelic MYO5B mutations (Table 1). One of the 11 
patients (18%) with at least one PTC-inducing muta-
tion and 9 of the 11 patients (82%) without a PTC 
mutation developed CLD. There was a significant 
relationship between the two variables (chi squared 
[1, n = 22] = 8.9, P < 0.01). There was also a significant 
relationship between the two variables when omitting 
multiple patients with the same mutation (chi square 
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[1, n  =  17]  =  4.5, P  <  0.05). While the inclusion of 
more patients will tell whether this relationship holds, 
the current numbers suggest that patients with PTC-
inducing MYO5B mutations have a reduced risk of 
developing CLD. Conceivably, with MYO5B expres-
sion abolished on one allele, the c.3163-3165dup 
(p.Leu1055dup) mutation (a common single-nucle-
otide polymorphism [rs200219597; gnomad.broad 
insti tute.org]) in the MYO5B gene on the other allele 
(Table  1) may not provide a strong enough effect to 
cause CLD.
MYO5B Mutations Can 
Protect Against CLD in 
Patients With MVID
Intriguingly, 3 out of a group of 8 patients with 
MVID and MYO5B mutations who underwent intesti-
nal transplantation presented with posttransplantation 
onset of CLD, and others showed exacerbation of 
preexisting CLD.(13,15) Also, in our medical center, a 
patient with MVID developed cholestasis and pruri-
tus after receiving an intestinal transplant. His CLD 
resolved following rejection and subsequent removal of 
the graft. In addition, a patient with late-onset MVID 
presented with CLD after birth, which resolved at the 
moment when his enteral symptoms appeared. CLD 
did not return following a combined liver and intes-
tinal transplantation. These observations led to the 
suggestion that the onset or severity of CLD may be 
inversely related to intestinal function.(15,28)
Because MYO5B mutations cause total malab-
sorption due to villus and brush border atrophy 
and the mislocalization of many brush border pro-
teins,(10,11) a reduced bile acid absorption capacity 
in the ileum (through the solute carrier family 10 
member 2–encoded apical sodium-bile acid trans-
porter [ASBT])(30,31) can be expected. The conse-
quently expected reduction of recirculating bile acids 
may (partially) diminish the clinical CLD symptoms. 
Indeed, the interruption of the bile acid circulation 
taBle 1. Individual Nontransplanted patients With MVID and Reported MYO5B Variations and presence or absence of ClD
Variations of the Patient With CLD
Patients with MVID and at least one  
PTC-inducing MYO5B mutation
c.5139-1G > C(het)/c.2731delC (p.Arg911Alafs*6, het)† No
c.445C > T (p.Gln149Ter, het)/c.5383C > T (p.Arg1795Ter, het)† Yes
c.3163_3165dup (p.Leu1055dup, het)‡/c.2259_2262dup (p.Tyr755Glyfs*9, het)† No
c.3163_3165dup (p.Leu1055dup, het)‡/c.2259_2262dup (p.Tyr755Glyfs*9, het)† No
c.4399C > T (p.Gln1467Ter, hom*) No
c.1347delC (p.Phe450Leufs*30, het)2/c.3163_3165dup (p.Leu1055dup, het)‡ No
c.1347delC (p.Phe450Leufs*30, het)2/c.3163_3165dup (p.Leu1055dup, het)‡ No
c.445C > T (p.Gln149Ter, het)†/c.1021C > T (p.Gln341Ter, het)† No
c.1390C > T (p.Arg1064Ter, het)†/c.3514C > T (p.Gln1172Ter, het)† No
c.4366C > T (p.Gln1456Ter, hom)† No
c.4399C > T (p.Gln1467Ter, hom) No
Patients with MVID and no PTC-inducing MYO5B 
mutations
c.1222A > T (p.Ile408Phe, het)/c.1582C > T (p.Leu528Phe, het) Yes
c.1222A > T (p.Ile408Phe, het)/c.1582C > T (p.Leu528Phe, het) Yes
c.310 + 2dupT, het/c.1966C > T (p.Arg656Cys,het) Yes
c.1540T > C (p.Cys514Arg, het)/c.4460-1G > C, het Yes





c.656G > T (p.Arg219His, het)/c.4028T > C (p.Leu1343Pro, het) No
c.1979C > T (p.Pro660Leu, hom) No
†This mutation is expected to result in the expression of a truncated protein that retained its rab8-binding and rab11a-binding sites.
‡This variation is a common single-nucleotide polymorphism (rs200219597).
Abbreviations: het, heterozygous mutation; hom, homozygous mutation.
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between liver and intestine, through either intestinal 
graft removal, ileal exclusion, nasobiliary drainage, or 
partial external bile diversion, led to a (partial) remis-
sion of CLD in patients with MVID,(15) which is in 
line with the effectivity of these treatments in other 
patients with PFIC.(32) Thus, MYO5B mutations that 
reduce the bile acid absorption capacity of the intes-
tine may provide some protection against CLD.(15) 
Future studies are needed to address the bile acid pool 
and bile flow dynamics in the various patients with 
MYO5B mutations.
Conclusions and Future 
Perspectives
MYO5B is a new kid on the block in CLD. Different 
mutations in MYO5B display seemingly contradictory 
effects on the clinical presentation of CLD. It appears 
that variations in the clinical presentation of MYO5B-
related low-GGT CLD can be attributed to the 
coincident expression but unequal effects of MYO5B 
mutations in enterocytes versus hepatocytes (Fig.  1). 
Thus, (a combination of ) MYO5B mutations with a 
predicted mild effect on myosin Vb protein function 
can cause canalicular transport defects in hepatocytes 
but not (serious) problems in enterocytes, resulting in 
a BRIC/PFIC-like CLD. MYO5B missense mutations 
that have a more profound impact on myosin Vb pro-
tein function can cause similar (or stronger) canalic-
ular transport defects in hepatocytes. However, these 
additionally cause absorptive defects in the intestine 
and, in case of an expected mislocalization of ASBT, 
likely reduce ileal bile acid recirculation and thereby 
diminish the clinical presentation of CLD. PTC-
inducing mutations cause absorptive defects in the 
intestine but, as such, no apparent canalicular defects.
Of interest, the amount of bile acid that is 
absorbed in the intestine likely affects the bile acid 
synthesis and pool size through farnesoid X recep-
tor–fibroblast growth factor 19 signaling.(33) Future 
studies should address the size of the bile acid pool 
and bile flow dynamics in patients with MYO5B 
mutations.
For most patients with MVID, it remains uncertain 
whether CLD results from TPN and/or their MYO5B 
mutations. Current prevalence data on CLD in MVID 
(this study) versus that of non-MVID pediatric TPN 
cohorts suggest that MYO5B mutations in general do 
not predispose to TPN-associated CLD. Changing to 
a TPN formula with fish oil–based lipids may provide 
insight into the contribution of the TPN to MVID-
associated CLD. Knowledge as to whether given 
MYO5B mutations disrupt canalicular transport in 
hepatocytes will aid family counseling and therapeutic 
decision-making. Currently, a combined bowel–liver 
transplantation is considered for children with MVID 
to reduce the risk of posttransplantation exacerba-
tion or onset of CLD.(13,15) However, if not neces-
sary, the scarce donor liver may be used for another 
patient in need. Immunohistochemical analyses of the 
localization of bile canalicular transporters in patients’ 
liver biopsies may prove informative. Patient stem 
cell–derived hepatocytes(34) and liver–gut on-a-chip 
models(35) may provide powerful preclinical tools to 
assess the impact of the patient’s mutation(s) on bile 
canalicular transport. As a cautionary note, however, 
it should be emphasized that gene mutations are not 
likely to be the sole determinant of CLD as siblings 
with the same MYO5B mutations showed different 
disease courses.(4)
In contrast to familial CLDs that are caused by 
predominantly liver-specific genes, i.e., ABCB11 
(https://www.gtexp ortal.org/home/gene/ABCB11) 
and ABCB4 (https://www.gtexp ortal.org/home/gene/
ABCB4 ),(32) MYO5B-associated CLD should be 
viewed as a disease of the enterohepatic circulation, 
rather than of solely the liver. We expect that this may 
also apply to other familial CLDs caused by genes 
that are expressed in both liver and intestine (e.g., 
ATP8B1 or nuclear receptor subfamily 1 group H 
member 4(32)).
Clearly, a given (set of ) MYO5B mutation(s) 
unequally affects two organs which cooperatively 
control bile flow complicates the disease presenta-
tion. Therefore, to understand the development and 
natural course of the disease as well as postinter-
vention outcomes, a personalized patient/mutation- 
specific multiorgan system approach will be required.
Search Strategy and 
Selection Criteria
References for this review were identified 
through searches of PubMed with the search terms 
Hepatology, Vol. 72, No. 4, 2020 VAN IJZENDOORN ET AL.
1467
“MYO5B,” “cholestasis,” “microvillus inclusion dis-
ease,” and “liver” from the earliest records until May 
2020. The final reference list was generated on the 
basis of originality and relevance to the broad scope 
of this review.
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